The stock of Esperion Therapeutics Inc. (ESPR) has seen a -4.93% decrease in the past week, with a 24.23% gain in the past month, and a -13.46% decrease in the past quarter. The volatility ratio for the week is 5.74%, and the volatility levels for the past 30 days are at 7.18% for ESPR. The simple moving average for the last 20 days is 4.91% for ESPR’s stock, with a simple moving average of -9.52% for the last 200 days.
Is It Worth Investing in Esperion Therapeutics Inc. (NASDAQ: ESPR) Right Now?
Company’s 36-month beta value is 1.00.Analysts have differing opinions on the stock, with 6 analysts rating it as a “buy,” 3 as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ESPR is 194.16M, and currently, short sellers hold a 19.30% ratio of that floaft. The average trading volume of ESPR on October 22, 2024 was 3.73M shares.
ESPR) stock’s latest price update
Esperion Therapeutics Inc. (NASDAQ: ESPR)’s stock price has gone decline by -1.70 in comparison to its previous close of 2.06, however, the company has experienced a -4.93% decrease in its stock price over the last five trading days. globenewswire.com reported 2024-09-25 that ANN ARBOR, Mich., Sept. 25, 2024 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that on September 23, 2024, the Company granted one new employee 3,500 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan.
Analysts’ Opinion of ESPR
Many brokerage firms have already submitted their reports for ESPR stocks, with BofA Securities repeating the rating for ESPR by listing it as a “Underperform.” The predicted price for ESPR in the upcoming period, according to BofA Securities is $2.50 based on the research report published on June 20, 2024 of the current year 2024.
ESPR Trading at 10.41% from the 50-Day Moving Average
After a stumble in the market that brought ESPR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.44% of loss for the given period.
Volatility was left at 7.18%, however, over the last 30 days, the volatility rate increased by 5.74%, as shares surge +22.73% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +10.05% upper at present.
During the last 5 trading sessions, ESPR fell by -4.93%, which changed the moving average for the period of 200-days by -20.59% in comparison to the 20-day moving average, which settled at $1.93. In addition, Esperion Therapeutics Inc. saw -32.27% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ESPR starting from Warren Eric, who sale 107 shares at the price of $2.12 back on Oct 17 ’24. After this action, Warren Eric now owns 162,552 shares of Esperion Therapeutics Inc., valued at $227 using the latest closing price.
Warren Eric, the Officer of Esperion Therapeutics Inc., proposed sale 107 shares at $2.12 during a trade that took place back on Oct 17 ’24, which means that Warren Eric is holding shares at $227 based on the most recent closing price.
Stock Fundamentals for ESPR
Current profitability levels for the company are sitting at:
- 0.02 for the present operating margin
- 0.82 for the gross margin
The net margin for Esperion Therapeutics Inc. stands at -0.35. The total capital return value is set at 0.03.
Based on Esperion Therapeutics Inc. (ESPR), the company’s capital structure generated 2.65 points at debt to capital in total, while cash flow to debt ratio is standing at -0.05. The debt to equity ratio resting at -1.61. The interest coverage ratio of the stock is -20.7.
Currently, EBITDA for the company is -155.4 million with net debt to EBITDA at 74.0. When we switch over and look at the enterprise to sales, we see a ratio of 2.78. The receivables turnover for the company is 4.6for trailing twelve months and the total asset turnover is 0.79. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.97.
Conclusion
In a nutshell, Esperion Therapeutics Inc. (ESPR) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
